JP2023518818A5 - - Google Patents
Info
- Publication number
- JP2023518818A5 JP2023518818A5 JP2022557117A JP2022557117A JP2023518818A5 JP 2023518818 A5 JP2023518818 A5 JP 2023518818A5 JP 2022557117 A JP2022557117 A JP 2022557117A JP 2022557117 A JP2022557117 A JP 2022557117A JP 2023518818 A5 JP2023518818 A5 JP 2023518818A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- fgfr3
- radioimmunoconjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993622P | 2020-03-23 | 2020-03-23 | |
| US62/993,622 | 2020-03-23 | ||
| PCT/US2021/023755 WO2021195131A1 (en) | 2020-03-23 | 2021-03-23 | Fgfr3-targeted radioimmunoconjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518818A JP2023518818A (ja) | 2023-05-08 |
| JP2023518818A5 true JP2023518818A5 (https=) | 2024-03-29 |
Family
ID=77892654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557117A Pending JP2023518818A (ja) | 2020-03-23 | 2021-03-23 | Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230201384A1 (https=) |
| EP (1) | EP4126074A4 (https=) |
| JP (1) | JP2023518818A (https=) |
| KR (1) | KR20220157464A (https=) |
| CN (1) | CN115315274A (https=) |
| AR (1) | AR121643A1 (https=) |
| AU (1) | AU2021244464A1 (https=) |
| BR (1) | BR112022019226A2 (https=) |
| CA (1) | CA3176617A1 (https=) |
| CL (1) | CL2022002557A1 (https=) |
| IL (1) | IL295999A (https=) |
| MX (1) | MX2022011635A (https=) |
| TW (1) | TW202144008A (https=) |
| WO (1) | WO2021195131A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20240254A (es) * | 2021-12-20 | 2025-01-13 | Astrazeneca Uk Ltd | Compuestos dirigidos a egfr-cmet y usos de estos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| BR112017017700A2 (pt) * | 2015-02-19 | 2018-07-31 | Bioclin Therapeutics Inc | métodos, composições e kits para tratamento do câncer |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| MA48861A (fr) * | 2017-05-05 | 2020-04-01 | Fusion Pharmaceuticals Inc | Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations |
| CN111868260B (zh) * | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| AU2021206233A1 (en) * | 2020-01-10 | 2022-08-11 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
-
2021
- 2021-03-23 KR KR1020227036615A patent/KR20220157464A/ko active Pending
- 2021-03-23 EP EP21775240.1A patent/EP4126074A4/en not_active Withdrawn
- 2021-03-23 AU AU2021244464A patent/AU2021244464A1/en not_active Abandoned
- 2021-03-23 JP JP2022557117A patent/JP2023518818A/ja active Pending
- 2021-03-23 CA CA3176617A patent/CA3176617A1/en active Pending
- 2021-03-23 TW TW110110479A patent/TW202144008A/zh unknown
- 2021-03-23 MX MX2022011635A patent/MX2022011635A/es unknown
- 2021-03-23 US US17/906,857 patent/US20230201384A1/en active Pending
- 2021-03-23 WO PCT/US2021/023755 patent/WO2021195131A1/en not_active Ceased
- 2021-03-23 IL IL295999A patent/IL295999A/en unknown
- 2021-03-23 BR BR112022019226A patent/BR112022019226A2/pt unknown
- 2021-03-23 AR ARP210100720A patent/AR121643A1/es not_active Application Discontinuation
- 2021-03-23 CN CN202180023427.1A patent/CN115315274A/zh active Pending
-
2022
- 2022-09-21 CL CL2022002557A patent/CL2022002557A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8119132B2 (en) | Humanized anti-tag-72 monoclonal antibodies | |
| US11981741B2 (en) | Humanized anti-CD45 antibodies | |
| AU2019234468B2 (en) | Bispecific binding agents and uses thereof | |
| US20250325718A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| JP7836270B2 (ja) | 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物 | |
| JP2023529640A (ja) | 治療用コンジュゲート | |
| JP2023518818A5 (https=) | ||
| WO2024055040A2 (en) | Humanized anti-cd45 antibodies | |
| TW202204424A (zh) | 用於人類疾病之治療的ｃｄ３８抗體 | |
| TW202204336A (zh) | 標靶tem-1之放射免疫結合物及其用途 | |
| AU2024230810A1 (en) | Radioactive metal-labeled antibody, radioactive pharmaceutical, and compound | |
| JP2023550462A5 (https=) | ||
| KR102866721B1 (ko) | Dota-사전표적화된 방사면역요법을 위한 n-아세틸갈락토사미노 덴드론-제거제 | |
| WO2022178642A1 (en) | Antibodies to igf2r and methods | |
| Puchol Tarazona et al. | Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer | |
| JP2024504931A5 (https=) | ||
| JP2011519883A (ja) | ホジキンリンパ腫の処理方法へのｅｄ−ｂフィブロネクチンに対して特異的に結合する放射性ラベルされた分子の使用 | |
| US20250099635A1 (en) | Iimmunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| TW202607033A (zh) | 抗ｒｏｒ２抗體－放射性核種結合物 | |
| WO2017061602A1 (ja) | Ｃｄ１４７分子に特異的に結合する抗体およびその利用 | |
| JP2024540536A5 (https=) | ||
| WO2024243315A2 (en) | Multi-arm bifunctional chelators | |
| WO2025089383A1 (ja) | ２２５Ａｃ標識抗ＣＤＨ３抗体 | |
| WO2026067491A1 (zh) | 抗体或者抗体药物偶联物与其他治疗剂的组合的应用 |